These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 24120380)
1. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510 [TBL] [Abstract][Full Text] [Related]
7. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632 [TBL] [Abstract][Full Text] [Related]
8. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D; N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681 [TBL] [Abstract][Full Text] [Related]
9. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH; N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141 [TBL] [Abstract][Full Text] [Related]
12. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience. Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409 [TBL] [Abstract][Full Text] [Related]
14. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Arnold DM; Heddle NM; Cook RJ; Hsia C; Blostein M; Jamula E; Sholzberg M; Lin Y; Kassis J; Larratt L; Tinmouth A; Amini S; Schipperus M; Lim W; Vishnu P; Warner M; Carruthers J; Li N; Lane S; Kelton JG Lancet Haematol; 2020 Sep; 7(9):e640-e648. PubMed ID: 32853584 [TBL] [Abstract][Full Text] [Related]
16. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290 [TBL] [Abstract][Full Text] [Related]
18. Eltrombopag: a review of its use in patients with severe aplastic anaemia. McCormack PL Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916 [TBL] [Abstract][Full Text] [Related]
19. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Fu H; Zhang X; Han T; Mo X; Wang Y; Chen H; Han W; Wang J; Wang F; Yan C; Zhang Y; Sun Y; Liu K; Huang X; Xu L Bone Marrow Transplant; 2019 Aug; 54(8):1310-1318. PubMed ID: 30664724 [TBL] [Abstract][Full Text] [Related]